全球藥用塗層球囊市場：市場規模、佔有率和趨勢分析（按產品類型、應用、最終用戶和地區分類）—市場機會分析和行業預測（2026-2036 年）

全球藥用塗層球囊市場預計將從2026年的12.8億美元成長到2036年的29.5億美元，預測期內複合年成長率（CAGR）為8.7%。本報告透過評估當前行業趨勢、技術進步、不斷變化的競爭格局以及主要產品類型、應用、終端用戶和地區未來的成長機遇，對全球市場進行了全面分析。

藥物塗層球囊（DCB）的出現，標誌著血管內治療領域的重大進展。它無需植入永久性植入，即可將抗增殖藥物局部遞送至病變血管。由於其能夠降低血管再阻塞、保護血管解剖結構並改善長期臨床療效，這些裝置已被臨床廣泛接受，用於治療周邊動脈疾病（PAD）、支架內再血管再阻塞（ISR）和其他複雜血管病變。球囊塗層技術、藥物傳遞機制、導管設計和病變準備技術的不斷進步，顯著提高了手術成功率、藥物遞送效率和治療的永續性。同時，全球心血管疾病負擔的加重、糖尿病和周邊血管疾病盛行率的上升、微創血管介入治療的日益普及以及無支架治療策略的廣泛應用，都為市場成長創造了有利條件。

本報告對影響市場表現的各項因素進行了詳細評估，並深入分析了行業趨勢、技術應用、監管動態、報銷方案以及競爭格局。報告還檢驗了不斷變化的客戶需求、投資趨勢、產品創新、商業化策略以及產業相關人員採取的策略聯盟。本報告旨在為藥用包衣球囊整個價值鏈上的相關人員提供可靠的市場資訊和長期預測，從而支持其策略規劃。

市場動態

由於周邊動脈疾病的盛行率不斷上升、對微創血管介入治療的需求日益成長，以及臨床上越來越傾向於無支架治療，藥物塗層球囊市場持續擴張。醫療機構擴大採用藥物塗層球囊來降低血管再阻塞、提高血管通暢性，並最大限度地減少與永久性金屬植入相關的併發症。糖尿病相關血管併發症率的上升、心臟和周邊血管介入治療的增加、先進導管檢查室的普及以及醫療基礎設施的不斷完善，都在推動先進藥物塗層球囊技術的應用。此外，有強力的臨床證據支持藥物塗層球囊在治療複雜血管病變方面的有效性，這進一步增強了醫生的信心，並支持了市場的持續成長。

技術創新仍然是該市場的關鍵因素。紫杉醇塗層球囊和Sirolimus塗層球囊技術的持續進步、新型藥物載體配方、球囊表面塗層技術、導管輸送能力以及病灶形成裝置的不斷湧現，正在變革血管內手術。這些創新能夠提高藥物輸送效率，改善球囊在複雜解剖結構中的性能，減少血管損傷，並改善長期臨床療效。預計對下一代Sirolimus塗層球囊技術的投資增加、臨床適應症的拓展以及先進影像和血管內引導系統的整合，將加速產品創新，並擴大藥物塗層球囊在全球範圍內的臨床應用。

儘管市場前景樂觀，但仍有許多因素持續影響市場擴張。先進的藥物塗層球囊技術高成本、法規核准要求嚴格、不同醫療體系的報銷方案存在差異，以及特定藥物製劑長期安全性和有效性的持續臨床檢驗，都是阻礙市場更廣泛應用的重要障礙。此外，醫療機構在將新一代藥物塗層球囊技術融入日常臨床實踐的過程中，也面臨著病患選擇、病灶準備、手術複雜性以及醫師訓練等方面的挑戰。

儘管如此，該市場仍為製造商和投資者提供了巨大的機會。冠狀動脈血管再阻塞中藥物塗層球囊的日益普及、周邊血管介入治療中應用範圍的擴大、新興經濟體醫療保健投資的增加以及新一代藥物輸送平台的持續發展，預計將在未來幾年內支撐市場的持續成長。醫療設備製造商、醫療服務提供者、研究機構和介入性心臟病學專家之間的策略合作正在加速技術應用，同時也促進永續血管治療方案的發展。同時，市場參與企業必須應對價格競爭、不斷變化的監管要求、快速發展的塗層技術以及透過累積長期證據不斷證明其卓越的臨床療效等挑戰，才能保持永續的市場領先地位。

基於細分市場的分析

本報告按產品類型、應用、最終用戶和地區對藥用塗層球囊市場進行了詳細分析，幫助相關人員識別高成長細分市場和新興投資機會。

依產品類型分類，市場分析涵蓋紫杉醇塗層球囊、Sirolimus塗層球囊和其他藥物塗層球囊技術。紫杉醇塗層球囊憑藉其已確立的臨床證據、廣泛的監管批准以及在周邊動脈疾病(PAD) 和冠狀動脈血管再阻塞(ISR) 介入治療中的廣泛應用，繼續佔據顯著的市場佔有率。Sirolimus塗層球囊預計將在預測期內實現最快成長，這得益於其臨床應用的不斷拓展、良好的安全性以及越來越多的證據支持其在冠狀動脈和周圍血管應用中的長期療效。藥物製劑、塗層技術和球囊輸送系統的持續創新可望進一步提升這兩類產品類型的性能和臨床效用。

從適應症角度來看，本報告評估了周邊動脈疾病(PAD)、冠狀動脈疾病 (CAD) 和其他血管疾病的適應症。周邊動脈疾病仍然是最大的適應症領域，這主要得益於下肢動脈疾病盛行率的上升、糖尿病和慢性腎臟病周邊動脈疾病。對於冠狀動脈疾病，預計在預測期內將出現顯著成長，這主要得益於藥物塗層球囊在支架內血管再阻塞、小血管疾病、分叉病變和其他複雜冠狀動脈介入治療中的應用日益廣泛。不斷增加的臨床證據和不斷完善的治療指南正在進一步推動藥物塗層球囊技術在多種血管疾病適應症中的更廣泛應用。

本報告進一步按主要終端用戶類別分析了市場趨勢。醫院和心臟中心憑藉其先進的心血管基礎設施、經驗豐富的介入性心臟病專家和血管專家資源以及大量的複雜血管內手術，繼續佔據最大的市場佔有率。隨著醫療機構拓展其專業的介入性心臟病服務並採用先進的影像引導血管手術，心臟導管檢查室也經歷了顯著成長。由於微創門診介入心臟病學的普及、手術效率的提高以及對成本效益型患者照護的日益重視，預計門診手術中心在預測期內將實現顯著成長。

區域分析

本報告對北美、歐洲、亞太、拉丁美洲以及中東和非洲的市場趨勢進行了全面評估。各區域的分析涵蓋了心血管疾病盛行率、醫療基礎設施、報銷體系、法規環境、技術應用、醫師專業水準和競爭力等因素，從而全面展現各區域的成長動態。

北美目前在全球市場佔據重要佔有率，這得益於其先進的心血管醫療基礎設施、微創血管介入治療的廣泛應用、優惠的醫保報銷政策、周邊動脈疾病動脈疾病和冠狀動脈疾病患病率的不斷上升，以及眾多領先醫療設備製造商的強大影響力。持續的技術創新、不斷增加的藥物塗層球囊療法臨床證據以及對介入性心臟病學日益成長的投資，進一步鞏固了該地區的市場地位。

在歐洲，由於血管內治療的廣泛應用、有利的臨床指南、心血管專科護理的普及以及醫療現代化方面的持續投入，市場持續穩步成長。此外，該地區較早採用了先進的藥物塗層球囊技術，尤其是在周邊動脈疾病和冠狀動脈血管再阻塞的治療方面，這進一步推動了市場擴張。

預計亞太地區將在預測期內實現最快成長，主要促進因素包括心血管疾病負擔的迅速加重、醫療保健支出的不斷成長、先進心臟導管介入服務的可及性提高，以及主要新興經濟體對微創血管療法的日益普及。人們對血管疾病早期診斷和治療重要性的認知不斷提高，加之導管介入實驗室基礎設施的擴建和醫生專業技能的提升，全部區域的參與企業創造巨大的市場成長機會。

在拉丁美洲、中東和非洲，隨著各國政府持續投資醫療基礎設施、改善心血管專科護理服務以及推廣先進醫療技術的應用，預計將湧現出極具吸引力的長期發展機會。周邊動脈疾病診斷率的提高、微創血管介入治療的日益普及以及醫療服務提供者與醫療設備製造商之間合作的加強，預計將進一步推動全部區域的市場成長。

競爭格局

本報告對競爭格局進行了詳細評估，深入分析了主要產業參與者的策略定位。報告檢視了企業組合、業務策略、技術能力、新產品發布、併購、夥伴關係、聯盟、區域擴張、研發投資以及其他檢驗競爭環境的關鍵企業趨勢。

企業標竿分析使相關人員能夠根據產品系列、創新能力、區域佈局、策略重點和競爭優勢對市場參與企業進行比較。該報告還評估了不斷演變的競爭強度，這種競爭強度是由持續的產品創新、微創血管內治療的日益普及、藥物塗層球囊適應症​​的擴大以及對下一代藥物輸送技術投資的增加所驅動的。隨著對有效無支架血管介入治療的需求持續成長，製造商正致力於開發先進的球囊塗層技術、提高藥物輸送效率、增強導管輸送性能並積累可靠的長期臨床證據，同時透過戰略合作、醫生教育項目和持續的技術創新來鞏固其全球市場地位。

本報告涵蓋的主要公司概況包括 B. Braun SE、Becton, Dickinson and Company、Boston Scientific Corporation、Medtronic plc、Koninklijke Philips NV、BIOTRONIK SE & Co. KG、Cordis Corporation、Concept Medical Inc.、Acotec Scientific Holdings Limited 和 iVascular SLU。

如何使用此報告

• 我們提供可靠的市場規模估算和長期成長預測。
• 我們將評估關鍵市場促進因素、限制因素、機會、挑戰和新興產業趨勢。
• 確定具有高成長潛力的產品類型、應用、最終用戶和區域細分市場。
• 本報告評估了藥物塗層球囊整個生態系中不斷發展的技術和創新成果的採用。
• 我們根據主要參與者的產品系列、策略措施和競爭優勢對其進行基準評估。
• 我們為企業擴張、投資規劃、合作夥伴評估和產品開發策略提供支援。
• 我們為醫療設備製造商、醫療保健提供者、經銷商、投資者、顧問和其他行業相關人員提供可操作的見解。

主要問題的答案

• 全球化學塗層氣球市場目前的規模有多大？到 2036 年的成長前景如何？
• 哪些因素正在推動、限制和影響市場成長？
• 在預測期內，哪些機會和挑戰預計將影響該產業的發展？
• 您預計哪些產品類型、應用領域、最終用戶和區域細分市場將出現最強勁的成長？
• 您認為哪個地區最具吸引力的商業機會？
• 在這個市場中，有哪些主要公司在運作？它們是如何增強自身競爭力的？
• 在近期的技術發展、新產品發布、合作關係、收購和策略舉措中，哪些因素正在影響競爭格局？
• 相關人員如何利用本報告中提供的市場資訊來支持其策略規劃、投資決策、市場擴張和產品開發工作？

目錄

第1章：引言

第2章 分析方法

第3章執行摘要

• 市場概覽
• 基於分段的摘要
• 區域概況
• 競爭格局概述

第4章 市場概覽

• 市場動態
  • 促進因素
    • 臨床上越來越傾向於以「無支架」治療方法治療周邊動脈疾病
    • 糖尿病及相關複雜小血管疾病盛行率增加
  • 抑制因子
    • 針對紫杉醇塗層器械的持續安全隱患和監管審查
    • DCB的高成本和醫療保健系統的預算限制
  • 機會
    • 業務拓展至冠狀動脈介入治療及小血管疾病領域
    • 利用先進奈米技術開發下一代Sirolimus塗層球囊
  • 趨勢
    • Sirolimus塗層球囊在複雜介入治療的快速臨床應用
    • 在日間手術中心過渡到門診周邊血管手術
• 波特五力分析
• 監管前景和還款環境
• 價值鏈分析

第5章：全球化學塗層氣球市場：依產品類型分類

• 紫杉醇塗層球囊
• 塗有Sirolimus的球囊

第6章：全球化學塗層氣球市場：依應用領域分類

• 周邊動脈疾病（PAD）
• 冠狀動脈支架內血管再阻塞（ISR）
• 冠狀動脈微血管疾病
• 神經血管介入
• 其他

第7章 全球化學塗層氣球市場：依最終用戶分類

• 醫院/心臟中心
• 門診手術中心（ASC）
• 專科診所

第8章 全球化學塗層球囊市場：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 中東和非洲
  • UAE
  • 沙烏地阿拉伯
  • 其他中東和非洲國家

第9章 競爭情勢

• 大公司的策略
• 市佔率分析
• 策略發展
• 競爭性標竿分析

第10章：公司簡介

• Medtronic plc
• Boston Scientific Corporation
• Becton, Dickinson and Company（BD）
• Abbott Laboratories
• B. Braun Melsungen AG
• Cook Medical
• Terumo Corporation
• Koninklijke Philips NV（Royal Philips）
• Biotronik SE & Co. KG
• Cordis（Hellman & Friedman）
• Concept Medical Inc.
• Acotec Scientific Holdings Limited
• Lepu Medical Technology（Beijing）Co., Ltd.
• iVascular SLU
• Cardionovum GmbH
• Eurocor Tech GmbH
• Hexacath
• Surmodics, Inc.
• Teleflex Incorporated
• Endocor GmbH

第11章附錄

第12章：常見問題解答

The global Drug-Coated Balloon Market is projected to grow from USD 1.28 billion in 2026 to USD 2.95 billion by 2036, registering a CAGR of 8.7% during the forecast period. The report provides a comprehensive assessment of the global market by evaluating current industry dynamics, technological advancements, competitive developments, and future growth opportunities across major product types, applications, end users, and geographic regions.

Drug-coated balloons (DCBs) have emerged as an important advancement in endovascular intervention by enabling localized delivery of antiproliferative drugs to diseased blood vessels without leaving behind a permanent implant. These devices have gained widespread clinical acceptance for the treatment of peripheral artery disease (PAD), coronary in-stent restenosis (ISR), and other complex vascular lesions due to their ability to reduce restenosis, preserve vessel anatomy, and improve long-term clinical outcomes. Continuous advancements in balloon coating technologies, drug delivery mechanisms, catheter design, and lesion preparation techniques have significantly enhanced procedural success, drug transfer efficiency, and treatment durability. In parallel, the increasing global burden of cardiovascular diseases, rising prevalence of diabetes and peripheral vascular disorders, growing preference for minimally invasive vascular interventions, and expanding adoption of stent-less treatment strategies continue to create favorable conditions for market growth.

This report presents a detailed evaluation of the factors influencing market performance while providing strategic insights into industry trends, technology adoption, regulatory developments, reimbursement scenarios, and competitive positioning. It also examines evolving customer requirements, investment patterns, product innovation, commercialization strategies, and strategic collaborations adopted by industry participants. The study is designed to support strategic planning by providing reliable market intelligence and long-term forecasts for stakeholders operating across the drug-coated balloon value chain.

Market Dynamics

The market continues to expand due to the increasing prevalence of peripheral artery disease and coronary artery disease, growing demand for minimally invasive vascular interventions, and rising clinical preference for stent-less treatment approaches. Healthcare providers are increasingly adopting drug-coated balloons to reduce restenosis, improve vessel patency, and minimize complications associated with permanent metallic implants. The growing incidence of diabetes-related vascular complications, increasing procedural volumes in interventional cardiology and peripheral vascular interventions, expanding access to advanced catheterization laboratories, and continuous improvements in healthcare infrastructure are collectively driving the adoption of advanced drug-coated balloon technologies. Furthermore, favorable clinical evidence supporting the effectiveness of DCBs in treating complex vascular lesions continues to strengthen physician confidence and support sustained market growth.

Technological innovation remains one of the defining characteristics of this market. Continuous advancements in paclitaxel-coated and sirolimus-coated balloon technologies, novel drug carrier formulations, balloon surface coating techniques, catheter deliverability, and lesion preparation devices are transforming endovascular treatment procedures. These innovations enable more efficient drug transfer, improved balloon performance in complex anatomies, reduced vascular injury, and enhanced long-term clinical outcomes. Growing investments in next-generation sirolimus-coated balloon technologies, expansion of clinical indications, and increasing integration of advanced imaging and intravascular guidance systems are expected to accelerate product innovation and broaden the clinical applications of drug-coated balloons worldwide.

Despite favorable growth prospects, several factors continue to influence market expansion. The high cost associated with advanced drug-coated balloon technologies, stringent regulatory approval requirements, reimbursement variability across healthcare systems, and continued clinical scrutiny regarding long-term safety and effectiveness of certain drug formulations remain important barriers to broader market adoption. Healthcare providers also face challenges related to patient selection, lesion preparation, procedural complexity, and physician training while integrating newer-generation DCB technologies into routine clinical practice.

The market nevertheless presents considerable opportunities for manufacturers and investors. Increasing adoption of drug-coated balloons for coronary in-stent restenosis, expanding utilization in peripheral vascular interventions, growing healthcare investments across emerging economies, and continuous development of next-generation drug-delivery platforms are expected to support sustained market growth over the coming years. Strategic collaborations among medical device manufacturers, healthcare providers, research institutions, and interventional cardiology specialists are accelerating technology adoption while facilitating the development of innovative vascular treatment solutions. At the same time, market participants must address competitive pricing pressures, evolving regulatory requirements, rapidly advancing coating technologies, and the need to continuously demonstrate superior clinical outcomes through long-term evidence generation to maintain sustainable market leadership.

Segment Analysis

The report provides an extensive analysis of the drug-coated balloon market across product type, application, end user, and geography, enabling stakeholders to identify high-growth segments and emerging investment opportunities.

Based on product type, the market is analyzed across paclitaxel-coated balloons, sirolimus-coated balloons, and other drug-coated balloon technologies. Paclitaxel-coated balloons continue to account for a significant share of the market owing to their well-established clinical evidence, widespread regulatory approvals, and extensive use in peripheral artery disease (PAD) and coronary in-stent restenosis (ISR) interventions. Sirolimus-coated balloons are expected to witness the fastest growth during the forecast period due to increasing clinical adoption, favorable safety profile, and growing evidence supporting their long-term efficacy in coronary and peripheral vascular applications. Continuous innovation in drug formulations, coating technologies, and balloon delivery systems is expected to further enhance the performance and clinical utility of both product categories.

From an application perspective, the report evaluates peripheral artery disease (PAD), coronary artery disease (CAD), and other vascular applications. Peripheral artery disease continues to represent the largest application segment owing to the increasing prevalence of lower limb arterial disease, growing incidence of diabetes and chronic kidney disease, and widespread use of drug-coated balloons in femoropopliteal interventions. Coronary artery disease is expected to register substantial growth during the forecast period, supported by increasing adoption of drug-coated balloons for the treatment of in-stent restenosis, small vessel disease, bifurcation lesions, and other complex coronary interventions. Expanding clinical evidence and evolving treatment guidelines are further supporting the broader adoption of drug-coated balloon technologies across multiple vascular applications.

The study further analyzes market performance across major end-user categories. Hospitals and cardiac centers continue to account for the largest share of the market owing to their advanced cardiovascular infrastructure, availability of experienced interventional cardiologists and vascular specialists, and higher procedural volumes involving complex endovascular interventions. Cardiac catheterization laboratories are also witnessing significant growth as healthcare providers continue expanding specialized interventional cardiology services and adopting advanced imaging-guided vascular procedures. Ambulatory surgical centers are expected to register notable growth during the forecast period due to the increasing shift toward minimally invasive outpatient cardiovascular interventions, improved procedural efficiency, and growing emphasis on cost-effective patient care.

Regional Analysis

The report offers a comprehensive assessment of market performance across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Each regional analysis considers cardiovascular disease prevalence, healthcare infrastructure, reimbursement frameworks, regulatory environments, technology adoption, physician expertise, and competitive intensity to provide a holistic understanding of regional growth dynamics.

North America currently represents a significant share of the global market owing to its advanced cardiovascular care infrastructure, widespread adoption of minimally invasive vascular interventions, favorable reimbursement policies, increasing prevalence of peripheral and coronary artery diseases, and the strong presence of leading medical device manufacturers. Continuous technological innovation, expanding clinical evidence supporting drug-coated balloon therapies, and growing investments in interventional cardiology continue to strengthen the region's market position.

Europe continues to demonstrate stable market growth, supported by increasing adoption of endovascular treatment procedures, favorable clinical guidelines, expanding access to specialized cardiovascular care, and ongoing investments in healthcare modernization. The region has also witnessed early adoption of advanced drug-coated balloon technologies, particularly for peripheral artery disease and coronary in-stent restenosis, further supporting market expansion.

Asia-Pacific is expected to register the fastest growth during the forecast period due to the rapidly increasing burden of cardiovascular diseases, expanding healthcare expenditure, improving access to advanced interventional cardiology services, and rising adoption of minimally invasive vascular procedures across major developing economies. Increasing awareness regarding early diagnosis and treatment of vascular diseases, coupled with expanding catheterization laboratory infrastructure and improving physician expertise, is creating significant growth opportunities for market participants throughout the region.

Latin America and the Middle East & Africa are also expected to present attractive long-term opportunities as governments continue investing in healthcare infrastructure, improving access to specialized cardiovascular care, and promoting the adoption of advanced medical technologies. Increasing diagnosis rates of peripheral and coronary artery diseases, expanding availability of minimally invasive vascular interventions, and growing collaborations between healthcare providers and medical device manufacturers are expected to further support market growth across these emerging regions.

Competitive Landscape

The report presents a detailed evaluation of the competitive landscape, offering valuable insights into the strategic positioning of major industry participants. It examines company portfolios, business strategies, technological capabilities, product launches, mergers and acquisitions, partnerships, collaborations, geographic expansion initiatives, research and development investments, and other significant corporate developments shaping the competitive environment.

Company benchmarking enables stakeholders to compare market participants based on their product portfolios, innovation capabilities, regional presence, strategic priorities, and competitive strengths. The report also evaluates the evolving competitive intensity resulting from continuous product innovation, increasing adoption of minimally invasive endovascular procedures, expansion of drug-coated balloon indications, and growing investments in next-generation drug delivery technologies. As demand for effective stent-less vascular interventions continues to increase, manufacturers are focusing on developing advanced balloon coating technologies, improving drug transfer efficiency, enhancing catheter deliverability, and generating robust long-term clinical evidence while strengthening their global market presence through strategic collaborations, physician education initiatives, and continuous technological innovation.

Key companies profiled in the report include B. Braun SE, Becton, Dickinson and Company, Boston Scientific Corporation, Medtronic plc, Koninklijke Philips N.V., BIOTRONIK SE & Co. KG, Cordis Corporation, Concept Medical Inc., Acotec Scientific Holdings Limited, and iVascular S.L.U.

How This Report Helps

• Provides reliable market size estimates and long-term growth forecasts.
• Evaluates major market drivers, restraints, opportunities, challenges, and emerging industry trends.
• Identifies high-growth product type, application, end-user, and regional segments.
• Assesses evolving technology adoption and innovation across the drug-coated balloon ecosystem.
• Benchmarks leading companies based on their product portfolios, strategic initiatives, and competitive positioning.
• Supports business expansion, investment planning, partnership evaluation, and product development strategies.
• Delivers actionable insights for medical device manufacturers, healthcare providers, distributors, investors, consultants, and other industry stakeholders.

Key Questions Answered

• What is the current size of the global drug-coated balloon market, and what is its projected growth through 2036?
• Which factors are driving, restraining, and influencing market growth?
• What opportunities and challenges are expected to shape the industry during the forecast period?
• Which product type, application, end-user, and regional segments are expected to witness the strongest growth?
• Which regions are expected to offer the most attractive business opportunities?
• Who are the leading companies operating in the market, and how are they strengthening their competitive positions?
• What recent technological developments, product launches, partnerships, acquisitions, and strategic initiatives are influencing the competitive landscape?
• How can stakeholders leverage market intelligence from this report to support strategic planning, investment decisions, market expansion, and product development initiatives?

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Scope
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Data Sources
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research
• 2.3. Market Size Estimation
  • 2.3.1. Bottom-up Approach
  • 2.3.2. Top-down Approach
• 2.4. Assumptions

3. Executive Summary

• 3.1. Market Snapshot
• 3.2. Segmental Summary
• 3.3. Regional Summary
• 3.4. Competitive Snapshot

4. Market Overview

• 4.1. Introduction
• 4.2. Market Dynamics
  • 4.2.1. Drivers
    • 4.2.1.1. Growing Clinical Preference for 'Stent-less' Therapies in Peripheral Arteries
    • 4.2.1.2. Rising Prevalence of Diabetes and Associated Complex Small Vessel Disease
  • 4.2.2. Restraints
    • 4.2.2.1. Lingering Safety Concerns and Regulatory Scrutiny Regarding Paclitaxel-Coated Devices
    • 4.2.2.2. High Cost of DCBs and Budgetary Constraints in Healthcare Systems
  • 4.2.3. Opportunities
    • 4.2.3.1. Expansion into Primary Coronary Interventions and Small Vessel Disease
    • 4.2.3.2. Development of Next-Generation Sirolimus-Coated Balloons with Advanced Nanotechnology
  • 4.2.4. Trends
    • 4.2.4.1. Rapid Clinical Adoption of Sirolimus-Coated Balloons in Complex Interventions
    • 4.2.4.2. Shift Toward Outpatient Peripheral Vascular Procedures in ASCs
• 4.3. Porter's Five Forces Analysis
• 4.4. Regulatory Outlook and Reimbursement Landscape
• 4.5. Value Chain Analysis

5. Global Drug-Coated Balloon Market, by Product Type

• 5.1. Paclitaxel-Coated Balloons
• 5.2. Sirolimus-Coated Balloons

6. Global Drug-Coated Balloon Market, by Application

• 6.1. Peripheral Artery Disease (PAD)
• 6.2. Coronary In-Stent Restenosis (ISR)
• 6.3. Coronary Small Vessel Disease
• 6.4. Neurovascular Interventions
• 6.5. Others

7. Global Drug-Coated Balloon Market, by End User

• 7.1. Hospitals & Cardiac Centers
• 7.2. Ambulatory Surgical Centers (ASCs)
• 7.3. Specialty Clinics

8. Global Drug-Coated Balloon Market, by Geography

• 8.1. North America
  • 8.1.1. U.S.
  • 8.1.2. Canada
• 8.2. Europe
  • 8.2.1. Germany
  • 8.2.2. U.K.
  • 8.2.3. France
  • 8.2.4. Italy
  • 8.2.5. Spain
  • 8.2.6. Rest of Europe
• 8.3. Asia Pacific
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. India
  • 8.3.4. South Korea
  • 8.3.5. Rest of Asia Pacific
• 8.4. Latin America
  • 8.4.1. Brazil
  • 8.4.2. Argentina
  • 8.4.3. Mexico
  • 8.4.4. Rest of Latin America
• 8.5. Middle East & Africa
  • 8.5.1. UAE
  • 8.5.2. Saudi Arabia
  • 8.5.3. Rest of Middle East & Africa

9. Competitive Landscape

• 9.1. Key Players Strategies
• 9.2. Market Share Analysis
• 9.3. Strategic Developments
• 9.4. Competitive Benchmarking

10. Company Profiles

• 10.1. Medtronic plc
• 10.2. Boston Scientific Corporation
• 10.3. Becton, Dickinson and Company (BD)
• 10.4. Abbott Laboratories
• 10.5. B. Braun Melsungen AG
• 10.6. Cook Medical
• 10.7. Terumo Corporation
• 10.8. Koninklijke Philips N.V. (Royal Philips)
• 10.9. Biotronik SE & Co. KG
• 10.10. Cordis (Hellman & Friedman)
• 10.11. Concept Medical Inc.
• 10.12. Acotec Scientific Holdings Limited
• 10.13. Lepu Medical Technology (Beijing) Co., Ltd.
• 10.14. iVascular S.L.U.
• 10.15. Cardionovum GmbH
• 10.16. Eurocor Tech GmbH
• 10.17. Hexacath
• 10.18. Surmodics, Inc.
• 10.19. Teleflex Incorporated
• 10.20. Endocor GmbH

11. Appendix

• 11.1. Disclaimer

12. Key Questions Answered